Navigation Links
Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Date:12/6/2011

ANAHEIM, Calif., Dec. 6, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the Oppenheimer Healthcare Conference to be held on December 13-14, 2011 in New York.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Tuesday, December 13, 2011 at 2:45 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit www.questcor.com.

 


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
2. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
3. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
4. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
9. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
10. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
11. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... ... August 21, 2017 , ... ... Island of Hawaii, is pleased to announce the first Delos Wellness Signature™ residence ... Sotheby’s International Realty is working together with listing agent Kelly Allen, R(S) of ...
(Date:8/21/2017)... Baltimore, Maryland (PRWEB) , ... August 21, 2017 ... ... has partnered with a leading Chinese bio security firm, to bring its proprietary ... As part of the relationship, the Chinese firm has purchased an undisclosed ...
(Date:8/21/2017)... Linda, Ca (PRWEB) , ... August 21, 2017 ... ... has arranged for two speakers for this two-part educational webinar, in which attendees ... complex subunit, and associated protein factor composition. Along with an overview of the ...
(Date:8/18/2017)... ... August 18, 2017 , ... Producers of ... Federal Hybrids, Inc. in an upcoming episode, scheduled to broadcast fourth quarter 2017. ... explore Federal Hybrids, the independent, family-owned seed company. Educating audiences about its broad ...
Breaking Biology Technology:
(Date:3/29/2017)...  higi, the health IT company that operates the ... , today announced a Series B investment from ... The new investment and acquisition accelerates higi,s strategy to ... population health activities through the collection and workflow integration ... collects and secures data today on behalf of over ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... 21, 2017 Optimove , provider ... retailers such as 1-800-Flowers and AdoreMe, today announced ... and Replenishment. Using Optimove,s machine learning algorithms, these ... and replenishment recommendations to their customers based not ... of customer intent drawn from a complex web ...
Breaking Biology News(10 mins):